Ubiquitylation of Nuclear Receptors: New Linkages and Therapeutic Implications

Overview

Journal J Mol Endocrinol

Specialties Endocrinology
Molecular Biology

Date 2015 May 7

PMID 25943391

Citations 25

Authors

Kyle T Helzer

Christopher Hooper

Shigeki Miyamoto

Elaine T Alarid

Affiliations

Soon will be listed here.

Abstract

The nuclear receptor (NR) superfamily is a group of transcriptional regulators that control multiple aspects of both physiology and pathology and are broadly recognized as viable therapeutic targets. While receptor-modulating drugs have been successful in many cases, the discovery of new drug targets is still an active area of research, because resistance to NR-targeting therapies remains a significant clinical challenge. Many successful targeted therapies have harnessed the control of receptor activity by targeting events within the NR signaling pathway. In this review, we explore the role of NR ubiquitylation and discuss how the expanding roles of ubiquitin could be leveraged to identify additional entry points to control receptor function for future therapeutic development.

Citing Articles

Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes.

Sereda E, Kolegova E, Kakurina G, Korshunov D, Sidenko E, Doroshenko A Transl Breast Cancer Res. 2024; 3:23.

PMID: 38751528 PMC: 11093047. DOI: 10.21037/tbcr-22-22.

Ubiquitination and deubiquitination in the regulation of N-methyladenosine functional molecules.

Zhao Y, Huang J, Zhao K, Li M, Wang S J Mol Med (Berl). 2024; 102(3):337-351.

PMID: 38289385 DOI: 10.1007/s00109-024-02417-9.

Regulation of PXR in drug metabolism: chemical and structural perspectives.

Gee R, Huber A, Chen T Expert Opin Drug Metab Toxicol. 2024; 20(1-2):9-23.

PMID: 38251638 PMC: 10939797. DOI: 10.1080/17425255.2024.2309212.

Estrogen Receptor Signaling in Breast Cancer.

Miziak P, Baran M, Blaszczak E, Przybyszewska-Podstawka A, Kalafut J, Smok-Kalwat J Cancers (Basel). 2023; 15(19).

PMID: 37835383 PMC: 10572081. DOI: 10.3390/cancers15194689.

Human nuclear hormone receptor activity contributes to malaria parasite liver stage development.

Mittal N, Davis C, McLean P, Calla J, Godinez-Macias K, Gardner A Cell Chem Biol. 2023; 30(5):486-498.e7.

PMID: 37172592 PMC: 10878326. DOI: 10.1016/j.chembiol.2023.04.011.

References

Callige M, Kieffer I, Richard-Foy H . CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol. 2005; 25(11):4349-58. PMC: 1140630. DOI: 10.1128/MCB.25.11.4349-4358.2005. View

Zhao J, Zhang Z, Vucetic Z, Soprano K, Soprano D . HACE1: A novel repressor of RAR transcriptional activity. J Cell Biochem. 2009; 107(3):482-93. PMC: 2736627. DOI: 10.1002/jcb.22146. View

Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M . Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol. 2006; 26(21):7966-76. PMC: 1636734. DOI: 10.1128/MCB.00713-06. View

Calvo V, Beato M . BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res. 2011; 71(9):3422-31. DOI: 10.1158/0008-5472.CAN-10-3670. View

Hwang C, Shemorry A, Auerbach D, Varshavsky A . The N-end rule pathway is mediated by a complex of the RING-type Ubr1 and HECT-type Ufd4 ubiquitin ligases. Nat Cell Biol. 2010; 12(12):1177-85. PMC: 3003441. DOI: 10.1038/ncb2121. View

Stavreva D, Muller W, Hager G, Smith C, McNally J . Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol Cell Biol. 2004; 24(7):2682-97. PMC: 371101. DOI: 10.1128/MCB.24.7.2682-2697.2004. View

Cardozo C, Michaud C, Ost M, Fliss A, Yang E, Patterson C . C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch Biochem Biophys. 2003; 410(1):134-40. DOI: 10.1016/s0003-9861(02)00680-x. View

Gronemeyer H, Gustafsson J, Laudet V . Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov. 2004; 3(11):950-64. DOI: 10.1038/nrd1551. View

Totta P, Pesiri V, Marino M, Acconcia F . Lysosomal function is involved in 17β-estradiol-induced estrogen receptor α degradation and cell proliferation. PLoS One. 2014; 9(4):e94880. PMC: 3988130. DOI: 10.1371/journal.pone.0094880. View

10.

Miesfeld R, Okret S, Wikstrom A, Wrange O, Gustafsson J, Yamamoto K . Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells. Nature. 1984; 312(5996):779-81. DOI: 10.1038/312779a0. View

11.

Mao C, Patterson N, Cherian M, Aninye I, Zhang C, Montoya J . A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem. 2008; 283(19):12819-30. PMC: 2442351. DOI: 10.1074/jbc.M709936200. View

12.

La Rosa P, Marino M, Acconcia F . 17β-estradiol regulates estrogen receptor α monoubiquitination. IUBMB Life. 2011; 63(1):49-53. DOI: 10.1002/iub.414. View

13.

Peng D, Zeng M, Muromoto R, Matsuda T, Shimoda K, Subramaniam M . Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J Immunol. 2011; 186(10):5638-47. PMC: 3914214. DOI: 10.4049/jimmunol.1003801. View

14.

Al-Hakim A, Zagorska A, Chapman L, Deak M, Peggie M, Alessi D . Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J. 2008; 411(2):249-60. DOI: 10.1042/BJ20080067. View

15.

Ramamoorthy S, Nawaz Z . E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal. 2008; 6:e006. PMC: 2329825. DOI: 10.1621/nrs.06006. View

16.

Powers G, Ellison-Zelski S, Casa A, Lee A, Alarid E . Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene. 2009; 29(10):1509-18. PMC: 2837136. DOI: 10.1038/onc.2009.434. View

17.

Mitsiades C, Davies F, Laubach J, Joshua D, San Miguel J, Anderson K . Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011; 29(14):1916-23. DOI: 10.1200/JCO.2010.34.0760. View

18.

Alarid E, Bakopoulos N, Solodin N . Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol. 1999; 13(9):1522-34. DOI: 10.1210/mend.13.9.0337. View

19.

Yang C, Gonzalez-Angulo A, Reuben J, Booser D, Pusztai L, Krishnamurthy S . Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006; 17(5):813-7. DOI: 10.1093/annonc/mdj131. View

20.

Hershko A, Ciechanover A . The ubiquitin system. Annu Rev Biochem. 1998; 67:425-79. DOI: 10.1146/annurev.biochem.67.1.425. View